
Exciting developments at the ASH Annual Meeting and Exposition
The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field
The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field
Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified
Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s
Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that it will present a poster
Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to
Jeremy Skillington, the CEO of Poolbeg Pharma, will be presenting at the Cell & Gene Therapy International Europe 2024 event. His presentation will focus on a novel approach using p38
The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods,